Conquering Diseases

Study of Investigational Treatment for Hearing Impaired Infants

Description

Study of whether treatment of congenital cytomegalovirus (cCMV) in infants who have experienced hearing-impairment reduces the loss in left or right ear hearing.

Overview

We are doing this study to compare the hearing and language outcomes of infants who receive 6 months of the investigational drug, valganciclovir, with children that do not receive valganciclovir. We also want to learn about safety and if there are any side effects of giving valganciclovir to infants with hearing loss caused by CMV

What we're hoping for

We are hoping to determine the most effective treatment for reducing the hearing loss in cCMV-infected infants.

Additional Information

ClinicalTrials.gov Identifier: NCT03107871

 Principal Investigator

Laura L Gibson, MD

University of Massachusetts Medical School

 Study Contact

Pediatrics Hem-Oncology  Research Center

774-441-8083

pedihemonc@umassmemorial.org

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989